DOCSLIB.ORG

Er Symposium EGID Les Grandes Avancées De La Recherche

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Er Symposium EGID Les Grandes Avancées De La Recherche Dossier de presse de Dossier European Genomic Institute for Diabetes er Symposium E.G.I.D. Les grandes avancées de la rechercheEuropean en diabétologie, le cru 200 Genomic Institute for Diabetes Date Mercredi 3 octobre 200 - 9h à 8h Lieu Conseil Régional Nord-Pas de Calais 5, avenue du Président Hoover 59555 Lille Cedex Page Dossier de presse de Dossier European Genomic Institute for Diabetes Sommaire o Communiqué de presse Page o Programme du symposium E.G.I.D. Page 3 o Présentation des équipes mutualisées au sein d’E.G.I.D Page 4 Génomique et maladies métaboliques - C.N.R.S. UMR 899 Directeur : Pr Philippe Froguel (Université Lille 2 Droit et Santé - CNRS - Institut Pasteur de Lille) Biothérapie du diabète - Inserm U 859 Directeur : Pr François Pattou (Université Lille 2 Droit et Santé - C.H.R.U. Lille - Inserm) Récepteurs nucléaires, maladies cardiovasculaires et diabète - Inserm U 011 European Directeur : Pr Bart Staels (Université Lille 2 Droit et SantéGenomic - Institut Pasteur de Lille - Inserm) Institute for Diabetes o Biographie des 9 spécialistes de renommée internationale qui débattront autour de la question sur « les grandes avancées de la recherche en diabétologie, le cru 200 » Page 7 José Florez (Harvard University) Oluf Pedersen (Steno Diabetes centre and Beijing Genomic Institute) Sadaf Farooqi (Cambridge University) Juleen Zierath (Karolinska University) Jorge Ferrer (University of Barcelona) Tony Vidal Puig (University of Cambridge) Ed Baetge (Novocell Inc, San Diego CA) Bernard Thorens (University of Lausanne) Alain Ktorza (Laboratoires Servier) o Présentation des partenaires institutionnels et de leur soutien à E.G.I.D Page 7 Pôle de Recherche et d’Enseignement Supérieur (PRES) Université Lille Nord de France Université Lille 2 Droit et Santé C.N.R.S. Inserm Institut Pasteur de Lille Conseil Régional Nord-Pas de Calais Page 2 Dossier de presse de Dossier European Genomic Institute for Diabetes Lille, le 06/09/2010 Le 3 octobre 200, E.G.I.D. organise son premier dans la région Nord-Pas de Calais une recherche de symposium renommée internationale et pluridisciplinaire. Il associe « Les grandes avancées de la recherche en des compétences scientifiques et médicales allant de la diabétologie, cru 200 » qui se tiendra au siège de recherche fondamentale à la recherche thérapeutique la Région Nord-Pas de Calais. appliquée au malade. Sa mission prioritaire est d’identifier les facteurs de risque des diabètes, de comprendre les E.G.I.D. (European Genomic Institute for Diabetes) mécanismes d’apparition de ses complications, afin de organise son premier symposium sur les grandes prévenir la survenue de cette maladie invalidante et de avancées de la recherche en diabétologie. A son appel, mieux traiter les patients. répondent 9 spécialistes de renommée internationale, qui se déplaceront le 13 octobre de toute l’Europe et Au sein d’E.G.I.D., trois des meilleures équipes des Etats-Unis pour débattre de cette question. A cette mondiales mutualisent des compétences complé- occasion, le prix du meilleur poster sur le diabète se mentaires : verra décerné à un jeune chercheur. European Genomic Institute for Diabetes - l’Unité Mixte de Recherche 8199 « Génomique Le diabète est un problème de santé publique qui et maladies métaboliques » dirigée par touche 200 millions de personnes dans le monde. En le Pr Philippe Froguel (Université Lille 2 – CNRS - Institut Europe, il est devenu une cause majeure de décès Pasteur de Lille) ; (maladies cardiovasculaires) et de handicap (cécité, amputation…). En outre, plus de 20 millions d’enfants - l’Unité 859 « Biothérapie du diabète » dirigée par le sont obèses ou en surpoids, et certains souffrent de Pr François Pattou (Université Lille 2 – CHRU de Lille troubles cardiovasculaires et de diabète. En France, – Inserm) ; la prévalence du diabète diagnostiqué est de 3 ,9 %, soit environ 2,5 millions de patients en 2007. Le Nord- - et l’Unité 1011 « Récepteurs nucléaires, maladies Pas de Calais est la région la plus touchée en France cardiovasculaires et diabète » dirigée par le Pr Bart Métropolitaine, puisque le taux de prévalence se situe Staels (Université Lille 2 – Institut Pasteur de Lille – actuellement à 4,8 %. Cent cinquante mille personnes Inserm) y sont traitées pour un diabète de type 2, chiffre qui a doublé en cinq ans. Le CNRS, l’Inserm, l’Université Lille 2 Droit et Santé, le CHRU de Lille, l’Institut Pasteur de Lille et la Région E.G.I.D. a été lancé le 25 mai 2009. Il s’agit du premier Nord-Pas de Calais unissent ainsi leurs forces pour lutter institut de recherche dédié spécifiquement au diabète contre ce problème de santé publique majeur qu’est le en France. Il a pour objectif de développer et ancrer diabète. Page Dossier de presse de Dossier European Genomic Institute for Diabetes Thèmes abordés • La révolution génétique et ses implications cliniques • De la génomique à la physiologie • Nouvel argument en faveur de l’hypothèse épigénétique • Le tissu adipeux et le syndrome métabolique • Avancées dans la recherche sur les cellules beta : des cellules souches aux nouveaux médicaments par : José Florez (Harvard University), Oluf Pedersen (Steno Diabetes centre and Beijing Genomic Institute), Sadaf Farooqi (Cambridge University), Juleen Zierath (Karolinska University), Jorge Ferrer (University of Barcelona), Tony Vidal Puig (University of Cambridge), Ed Baetge (Novocell Inc, San Diego CA), Bernard Thorens (University of Lausanne), Alain Ktorza (Laboratoires Servier) (voir programme détaillé joint) European Genomic Institute Le site internet d’E.G.I.D. for Diabetes Contacts presse Université Lille 2 Droit et Santé egid.univ-lille2.fr Virginie Lapierre Service Communication Tél. : +33 (0)3 20 96 43 35 Date Fax : +33 (0)3 20 96 45 95 Courriel : [email protected] mercredi 13 octobre 2010 de 9h à 18h (date limite de soumission du poster : Vincent Voisin 15 septembre 2010) Service de la Recherche, de la Valorisation (date limite d’inscription : et de l’Information Scientifique 1er octobre 2010 sur http://egid.fr) Tél. : +33 (0)3 20 96 52 66 Fax : +33 (0)3 20 96 52 23 Lieu Courriel : [email protected] Site internet : www.univ-lille2.fr Hôtel de Région Inserm Délégation Régionale Nord-Ouest 151 avenue du Président Hoover Aurélie Deleglise 59555 Lille Cedex (FRANCE) Service Communication Tél. : +33 (0)3 20 29 86 72 Fax : +33 (0)3 20 49 01 38 Courriel : [email protected] Page 2 Dossier de presse de Dossier European Genomic Institute for Diabetes Programme du er symposium E.G.I.D. Les grandes avancées de la recherche en diabétologie, le cru 200 European Genomic Institute 9h Accueil et affichage des posters for Diabetes pancréatiques 14h30 Le tissu adipeux et le syndrome 9h45 Mot d’accueil par Sandrine Rousseau, métabolique (30min) Vice-Présidente chargée de l’Enseignement Supérieur et de la Recherche Tony Vidal Puig (30 min) (University of au Conseil Régional Nord Pas-de Calais. Cambridge) Développement et lipotoxicité du tissue adipeux et syndrome métabolique – Une perspective 10h Mot d’accueil et présentation d’ E.G.I.D. allostatique (15 minutes) 15h Pause (30min) 10h15 La révolution génétique et ses implications cliniques (45 minutes) 15h30 Récompense du meilleur poster (15min) José Florez (Harvard University) 15h45 Avancées dans la recherche sur les cellules Effet clinique des facteurs génétiques prédictifs beta : des cellules souches aux nouveaux du diabète de type 2 médicaments (1h30) 11h Pause et session posters (30 min) Ed Baetge (30 min) (Novocell Inc, San Diego CA) 11h30 De la génomique à la physiologie (1h) Fonctions des cellules de l’ilôt pancréatique depuis les cellules souches embryonnaires Oluf Pedersen (30 min) (Steno Diabetes centre Bernard Thorens (30 min) (University of and Beijing Genomic Institute) Lausanne) Les nouveaux bio-marqueurs de risque du Nouvelles données sur GLP-1, prolifération et diabète de type 2 et ses complications apoptose de la cellule beta Sadaf Farooqi (30 min) (Cambridge University) Alain Ktorza (30 min) (Laboratoires Servier) Aperçus génétiques, moléculaires et Vers de nouveaux médicaments restaurant la physiologiques de l’obésité humaine fonction de la cellule beta 12h30 Repas et session posters (1h) 17h15 Conclusions L’accueil scientifique sera assuré par Philippe Froguel, 13h30 Nouvel argument en faveur de l’hypothèse L’animation scientifique du symposium sera assurée épigénétique (1h) par François Pattou, Les conclusions du jour seront données par Bart Staels Juleen Zierath (30 min) (Karolinska University) Role de la méthylation de l’ADN dans les tissus *** Le programme est susceptible d’être modifié périphériques sensibles à l’insuline : Implications pour le diabète de type 2. Jorge Ferrer (30 min) (University of Barcelona) Programmes transcriptionnels des cellules beta Page 3 Dossier de presse de Dossier European Genomic Institute for Diabetes Le diabète représente aujourd’hui une véritable menace pour la santé humaine. Pour comprendre et traiter cette maladie. Au sein d’E.G.I.D. (European Genomic Institute for Diabetes), trois des meilleures équipes mondiales mutualisent des compétences complémentaires : European Genomic Institute for Diabetes Titre : Génomique et maladies métaboliques CNRS UMR 8199 Directeur : Pr Philippe Froguel (Université Lille 2 Droit et Santé - CNRS - Institut Pasteur de Lille) ©DR Résumé : Créée en 1995 et co-fondatrice de l’Institut de Biologie de Lille, notre équipe a été constamment renouvelée depuis cette date. Nous constituons actuellement une Unité Mixte de Recherche du CNRS et de l’Université Lille Nord de France bénéficiant aussi du soutien de l’Institut Pasteur de Lille, située sur le campus Calmette Pasteurien. Notre unité comporte 37 personnes, chercheurs, ingénieurs, techniciens, administratifs et étudiants. Notre unité a publié 238 articles scientifiques depuis 10 ans (qui ont été cités 21 000 fois). Nos recherches portent essentiellement sur l’élucidation des bases génétiques du diabète et de l’obésité, maladies multifactorielles liées à la pression d’un environnement moderne « obésogène » sur des personnes vulnérables car porteuses d’une prédisposition familiale aux maladies métaboliques.
Load more

Recommended publications
  • Gut and Adipocyte Peptides
    Reviews/Commentaries/ADA Statements PERSPECTIVES ON THE NEWS Gut and Adipocyte Peptides ZACHARY T. BLOOMGARDEN, MD sented information pertaining to effects of GLP-1 on insulin action, noting that a ma- jor confounding factor is the increase in his is the third in a series of articles els are increased. The perfused pancreas portal insulin levels and the decrease in Ϫ Ϫ on presentations at the American isolated from GLP-1R / animals shows glycemia with GLP-1, both indirectly im- T Diabetes Association Annual Meet- normal insulin response to glucose, proving the glucose-lowering effect of insu- ing, San Diego, California, 10–14 June although without response to GLP-1. GLP- lin. GLP-1 concentrations are somewhat Ϫ Ϫ 2005. 1R / ␤-cells appear to have increased sen- lower in persons with diabetes and, to a sitivity to the incretin glucose-dependent lesser extent, with impaired glucose toler- Glucagon-like peptide-1 (and related insulinotropic polypeptide (GIP), perhaps ance, and GLP-1R activation is increased hormones) representing an adaptive upregulation of well beyond the physiologic range both Daniel Drucker (Toronto, Canada) re- GIP and/or of GIP response, and mice nei- with agonists and with administration of viewed evidence that the incretin effect, ther expressing the GLP-1 nor the GIP re- DPP-IV inhibitors. In vitro, GLP-1 increases the phenomenon of enteral glucose load- ceptor show glucose intolerance with adipocyte 2-deoxy-glucose uptake, rat so- ing increasing the insulin secretory re- decreased insulin response to glucose, and leus muscle glycogen synthesis, and hep- sponse to an increase in blood glucose, is fail to show a glucose-lowering response taocyte glycogen synthase A levels.
    [Show full text]
  • NIDDK Recent Advances and Emerging Opportunities February
    NIDDK: 60 Years of Discovery, 1950-2010 The NIDDK was established as the National Institute of Arthritis and Metabolic Diseases in 1950 by U.S. President Harry S. Truman. Sixty years and four name changes later, one thing has never changed: the Institute’s commitment to improving health through high-quality research. In 2010, NIDDK celebrated the rich history of advances made possible through the federal investment in research in our laboratories here in Bethesda, MD, and in Phoenix, AZ, and by grantees around the U.S. and beyond. NIDDK’S SCIENTIFIC SYMPOSIUM: CELEBRATES PAST, LOOKS TO FUTURE On Tuesday, September 21, 2010, NIDDK hosted, “Unlocking the Secrets of Science: Building the Foundation for Future Advances,” a scientific symposium to highlight research advances made possible, in part, with NIDDK support. NIDDK director, Dr. Griffin Rodgers, welcomed all in attendance to what promised to be an exciting day of cutting-edge scientific presentations. Former NIDDK directors Dr. Lester B. Salans (Mount Sinai Medical School and Forest Laboratories), Dr. Phillip Gorden (NIDDK), and Dr. Allen M. Spiegel (Albert Einstein College of Medicine) chaired scientific sessions on Diabetes and Digestive and Kidney Diseases; Nutrition, Hematology, and Urology; and Endocrinology, Education, Outreach, and the NIDDK Intramural Research Program. Each session featured three presentations from distinguished scientists spanning NIDDK’s research mission. Photo: Ernie Branson Session 1: Diabetes and Digestive and Kidney Diseases C. Ronald Kahn, M.D., Insulin
    [Show full text]
  • 75 Scientific Sessions Corporate Symposia At
    75th SCIENTIFIC SESSIONS CORPORATE SYMPOSIA AT-A-GLANCE FRIDAY, JUNE 5, 2015: 8:00 a.m. – 1:45 p.m. Turning Words into Action in Type 2 Diabetes Sponsored by Institute for Medical and Nursing Education, Inc. And International Medical Press Supported by an educational grant from AstraZeneca Contact: Edwin Odoemelam Phone: +44-207-398-0608 Email: [email protected] Location: Westin Boston Waterfront, Harbor Ballroom This highly interactive workshop is organized by the Global Partnership for Effective Diabetes Management and is designed for healthcare professionals from around the globe, focusing on the need for early glycemic control to reduce diabetes-related complications, and discussion on how to overcome barriers to achieving goals safely. 6:30 p.m. – 9:30 p.m. 6:30 p.m. – 7:00 p.m. – Registration and Dinner 7:00 p.m. – 9:30 p.m. – Educational Program El Panorama Cambiante Sobre el Tratamiento de la Diabetes Tipo 2 con Insulina (Presentado en Español) Jointly sponsored by University of Texas Southwestern Medical Center and Worldwide Initiative for Diabetes Education Supported by an unrestricted educational grant from Novo Nordisk Contacts: Mark Vinciguerra, University of Texas Southwestern Medical Center Phone/Email: 214-648-4852; [email protected] Jane Savio, Worldwide Initiative for Diabetes Education Phone/Email: 212-614-4337; [email protected] Location: Westin Boston Waterfront, Harbor Ballroom Este simposio se enfocará en insulinas y nuevas tendencias en terapias de insulina, como es que están redefiniendo el cuidado de la diabetes tipo 2 hoy en día y que esperanza están aportando para hacer frente a la creciente demanda mundial debido al crecimiento de la diabetes y sus complicaciones.
    [Show full text]
  • Characterization of Insulin Receptors in Patients with the Syndromes of Insulin Resistance and Acanthosis Nigricans
    Diabetologia 18, 209-216 (1980) Diabetologia by Springer-Verlag 1980 Characterization of Insulin Receptors in Patients with the Syndromes of Insulin Resistance and Acanthosis Nigricans R. S. Bar s, M. Muggeo, C. R. Kahn, Ph. Gorden, and J. Roth 1Division of Endocrinology, University of Iowa, Iowa City, Iowa, and Diabetes Branch, NIH, Bethesda, Maryland, USA Summary. This report analyzes the in vitro charac- patients have circulating antibodies which impair teristics of ~25I-insulin binding to the monocytes of insulin receptor function. The clinical course in some nine patients with the syndromes of acanthosis nigri- of these patients [5, 6] and a detailed description and cans and insulin resistance. The 3 Type A patients characterization of the autoantibodies to the insulin (without demonstrable autoantibodies to the insulin receptor have been reported previously [7-15]. receptor) had decreased binding of insulin due to a In the present study we have analyzed in greater decreased concentration of receptors. In these detail the interaction of insulin with its receptor on patients the residual receptors demonstrated normal the circulating monocytes of nine patients with these dissociation kinetics, negative cooperativity, and syndromes (3 Type A and 6 Type B) in order to were blocked by anti-receptor antibodies in a manner elucidate further the pathogenesis of these syn- similar to normal cells. In contrast, monocytes from dromes. the 6 Type B patients (with circulating anti-receptor autoantibodies) had decreased binding of insulin due to a decrease in receptor affinity. Insulin binding to Materials and Methods monocytes of Type B patients demonstrated acceler- ated rates of dissociation with no evidence of Patients cooperative interactions among insulin receptors.
    [Show full text]
  • A FRAUD THAT SHOOK the WORLD of SCIENCE - New Yo
    A FRAUD THAT SHOOK THE WORLD OF SCIENCE - New Yo... http://query.nytimes.com/gst/fullpage.html?res=9407EEDC1139F9... HOME PAGE MY TIMES TODAY'S PAPER VIDEO MOST POPULAR TIMES TOPICS Get Home Delivery Log In Register Now Wednesday, August 27, 2008 Health WORLD U.S. N.Y. / REGION BUSINESS TECHNOLOGY SCIENCE HEALTH SPORTS OPINION ARTS STYLE TRAVEL JOBS REAL ESTATE AUTOS RESEARCH FITNESS & NUTRITION MONEY & POLICY VIEWS HEALTH GUIDE A FRAUD THAT SHOOK THE WORLD OF SCIENCE Published: November 1, 1981 E-MAIL Morton Hunt writes frequently about science and psychology; his latest book, PRINT ''The Universe Within: A New Science Explores the Human Mind,'' will be published in February by Simon & Schuster. By Morton Hunt SAVE SHARE A Junior Scientist Accuses a Senior Scientist On a bright, cold morning in early February 1980, Jeffrey Flier, a tall, mustachioed young physician, boarded a train in Boston on his way to New Haven to carry out a distinctly disagreeable professional task. He was going to conduct an ''audit'' at the Yale University School of Medicine: He would spend some hours interrogating and examining the laboratory records of an associate professor there, one of whose published research papers on insulin metabolism had been called fraudulent by another researcher. Dr. Flier - he pronounces it ''flyer'' - was well qualified for the assignment. He had trained in diabetes research at the National Institutes of Health (N.I.H.) in Bethesda, and now, though only 31, he was chief of the diabetes metabolism unit of Beth Israel Hospital in Boston and an assistant professor at the Harvard Medical School.
    [Show full text]
  • CURRICULUM VITAE the Johns Hopkins University School of Medicine Rexford S. Ahima, MD, Phd DEMOGRAPHIC and PERSONAL INFORMATION
    CURRICULUM VITAE The Johns Hopkins University School of Medicine Rexford S. Ahima, MD, PhD DEMOGRAPHIC AND PERSONAL INFORMATION Current Appointments University 2016-present Professor of Medicine, The Johns Hopkins University School of Medicine 2016-present Professor of Public Health, The Johns Hopkins University School of Medicine 2016-present Professor of Nursing, The Johns Hopkins University School of Medicine 2016-present Bloomberg Distinguished Professor of Diabetes, The Johns Hopkins University School of Medicine 2016-present Director, Division of Endocrinology, Diabetes and Metabolism, The Johns Hopkins University School of Medicine 2016-present Adjunct Professor of Medicine, University of Pennsylvania, Perelman School of Medicine, Division of Endocrinology, Diabetes and Metabolism 2016-present Leader of Johns Hopkins Diabetes Initiative 2018-present Director, Johns Hopkins/University of Maryland Diabetes Research Center Hospital 1986-1987 Houseofficer in Medicine and Surgery, Korle Bu Teaching Hospital, Accra, Ghana 1998-1999 Associate Physician, Beth Israel Deaconess Medical Center, Boston, MA 1998-1999 Attending Endocrinologist, Beth Israel Deaconess Medical Center, Boston, MA 1999-2016 Staff Endocrinologist, Hospital of the University of Pennsylvania 1999-2016 Staff Endocrinologist, Presbyterian Medical Center 2016-present Staff Endocrinologist, Johns Hopkins Hospital 2016-present Staff Endocrinologist, Johns Hopkins Bayview Medical Center Other 1999-2016 Faculty, Institute of Neurological Sciences, University of Pennsylvania
    [Show full text]
  • A1984tu04300001
    TM Cc/NUMBER 50 This Week’s Citation Classic DECEMBER 10,1984 Kahn C R, Filer I S, Bar R S, Archer I A, Gorden P, Martin M M & Roth I. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N. Engi. I. Med. 294:739-45, 1976. [Diabetes Branch, Nati. Inst. Arthritis, Metabolism, and Digestive Dis.. NIH, Bethesda, Ml) and Dept. Pediatrics, Georgetown Univ. Sch. Med.. Washington, DCI Six patients are described representing two “As the medical community recognized syndromes of insulin resistance associated our interest in diseases associated with de- with acanthosis nigricans. The Type A pa- fects in insulin action, we were gradually re- I tients are young females with virilization and have insulin resistance due to a de- ferred several patients with syndromes of ex- crease in the number of insulin receptors on treme insulin resistance—some requiring cells. The Type B patients have an autoim- thousands of units of insulin per day. These mune syndrome with autoantibodies to the were clinically challenging cases, but even insulin receptor. [The SCI® indicates that more interestingin that they provided a way this paper has been cited in over 345 publi- to test the importance of the insulin recep- cations since 1976] tor. As we had hoped, when insulin binding to its receptor was measured using circulat- ing monocytes from these patients, there C. Ronald Kahn was a marked decrease. Jeffrey Flier recog- Research Division nized the importance of the immune fea- Joslin Diabetes Center tures in some of these patients and devel- One Joslin Place oped an assay to directly measure anti-re- Boston, MA 02215 ceptor antibodies.
    [Show full text]
  • Enabling the Collaboration Experience Broad Institute of MIT
    Broad Institute of MIT & Harvard Enabling the Collaboration Experience October 17, 2011 Overview 1. What is the Broad Institute? 2. What do we do? 3. How are we organized? 4. The Collaboration Experience 5. Challenges 6. Future 2 A brief organizational history 2002: Two major research groups come 2008: “Experiment” declared a success together • Broads announce new endowment of $400 million • Whitehead/MIT Center for Genome Research • Combined $600M Current Use + Endowment Gift • Harvard Institute of Chemistry and Cell Biology 2009: Broad Institute, Inc. established 2004: Broad Institute launched • 501(c)3 formed 9/08; Operations begin 7/09 • Initial $100M gift from Broad Foundations 2010: Carlos Slim foundation provides $65M • A 10-year “experiment” in collaborative science • New initiative in genomic disease research 2004 – 2009: Broad doubles in size • 1st U.S. collaboration to receive funding • Governed by MIT-Harvard leadership • Administratively managed within MIT 2006: 7CC headquarters building opens • 250,000 sq. ft. March 2006 fully occupied 2006: Broads double initial gift to $200M • Unrestricted for Broad research and operations 2007: Creation of new Stanley Center • Founding $100M, 10-year gift from Stanley Medical Research Institute From left: Eric Lander, Susan Hockfield, Drew Faust, Eli Broad, Edythe Broad, Deval Patrick, David Baltimore 3 Governance Educational, scientific and charitable 501(c)3 corporation Members of Corporation: • MIT • Harvard • The Eli and Edythe Broad Foundation Board of Directors (currently 15): fiduciary
    [Show full text]
  • Bittersweet Breakthroughs in Diabetes Research Experts Give Metabolic
    CELEBRATING OUR TENTH YEAR NEWS Bittersweet breakthroughs in diabetes research As the number of diabetes cases worldwide what causes the cells to die and intervene, if skyrockets, progress toward understanding you can prevent the progressive deterioration, the complex disease has been painstakingly it would be a breakthrough as well,”he says. slow. But promising new research on the links In the meantime, diabetes is still largely between obesity, the metabolic syndrome and treated with insulin injections. Other drugs in diabetes could bring new treatments into the use stimulate the pancreas to make more fray, experts say. insulin, decrease the amount of glucose According to the World Health produced by the liver, increase insulin Organization, more than 176 million people sensitivity or slow down starch absorption. worldwide have diabetes—nearly 95% of Two of the newer, more promising, drugs which is non-insulin-dependent type 2 target glucagon-like peptide-1 (GLP-1). diabetes—and the number is expected to GLP-1 stimulates insulin secretion, reduces more than double in 25 years. food intake and suppresses the hormone Because diabetes is a complex, polygenic glucagon. One GLP-1 analog (Nat. Med. 9, disease, progress has been slow, but steady, 1228; 2003) is being developed by Amylin says Alan Saltiel, director of the Life Sciences Martin Dohrn/Science Photo Library Pharmaceuticals, which plans to submit a new Institute at the University of Michigan. “We sensitivity, says Jeffrey Flier, chief academic drug application to the US Food and Drug are starting to learn about the complex officer at Beth Israel Deaconness Medical Administration in mid-2004.
    [Show full text]
  • BCS Bio Final
    Opening Session BREAST CANCER IN THE DEVELOPING WORLD: MEETING THE UNFORSEEN CHALLENGE TO WOMEN, HEALTH AND EQUITY Opening Session Opening Session Dr. Felicia Knaul Director, Harvard Global Equity Initiative Associate Professor, Harvard Medical School Felicia Knaul, MA, PhD (Economics, Harvard University) is the newly- appointed director of the Harvard Global Equity Initiative and Associate Professor at the Harvard Medical School. She is also a Senior Associate with the Mexican Health Foundation, where she has collaborated with since 1994. As a result of her personal experience, she founded Cáncer de Mama: Tómatelo a Pecho (Breast Cancer: Take it to Heart) in 2007, a program that undertakes and promotes research, advocacy, awareness and early detection initiatives on breast cancer in Latin America. Her book on her life with breast cancer “Tómatelo a Pecho” was released in October. Dr. Knaul has more than 100 publications and is a member of numerous organizations, including: Consultative Council of UNICEF in Mexico; Harvard-Mexico Foundation, Mexican Council on Competitiveness; and the High Level Early Childhood Development Secretariat at the Earth Institute of Columbia University. Dr. Knaul has held senior government posts at the Ministries of Education and Social Development in Mexico and at the Department of Planning of Colombia. She has worked for the WHO, World Bank, the Inter-American Development Bank and UNICEF. Dr. Knaul is Canadian, and resides in Boston and Mexico City. She and her husband, Dr. Julio Frenk, have two children, Hannah and Mariana Havivah. BREAST CANCER IN THE DEVELOPING WORLD: MEETING THE UNFORSEEN CHALLENGE TO WOMEN, HEALTH AND EQUITY 2 Opening Session Dr.
    [Show full text]
  • Leptin in Anorexia Nervosa and Amenorrhea
    Molecular Psychiatry (1997) 2, 267–269 1997 Stockton Press All rights reserved 1359–4184/97 $12.00 EDITORIAL Leptin in anorexia nervosa and amenorrhea In this issue of Molecular Psychiatry we publish two low leptin levels are a predictor of amenorrhea in low- articles by Hebebrand et al1 and Ko¨ pp et al2 on leptin, weight women. The authors show that in their popu- the product of the OB gene, which is synthesized by lation menstruation ceased to occur when leptin levels white fat cells, and acts in various organs, including were under the range of 1.85 mgL−1. In those subjects, the brain. Low leptin levels cause increases in food leptin levels were a better predictor of amenorrhea than intake and weight gain, and high leptin levels cause a BMI, fat mass, and percent body fat. The conclusion decrease in food intake, and increases in motor from the study is that a critical level of leptin is needed activity, energy metabolism, and body temperature, to maintain menstrual function. resulting in weight loss. The leptin receptor gene that Interestingly, studies conducted in the laboratory of has been cloned encodes five or more leptin receptor Jeffrey Flier have shown that the endocrine alterations isoforms, including a form predicted to be soluble, sev- that occur during starvation, such as increased adreno- eral short forms with small intracellular domains, and corticotropic hormone (ACTH) and cortisol levels, one long form with substantial homology to the sig- which are among the biological hallmarks of anorexia naling domain of the type I cytokine receptor family nervosa, can be reversed in food-deprived animals by that utilizes the JAK/STAT pathway for signal trans- the administration of exogenous leptin.7 Based on duction.3–5 The discoveries of leptin and leptin recep- those data, we have tested the hypothesis that in tors have created a new area of investigation in endo- humans endogenous leptin levels are inversely related crinology and metabolism.
    [Show full text]
  • Correlation Between CRP, Albumin and Obesity- a Systematic Review Sumaia Radi¹, Abdulmalik Altaf ², Noura Eid³
    International Journal of Academic Scientific Research ISSN: 2272-6446 Volume 5, Issue 2 (May - June 2017), PP 25 - 46 Correlation between CRP, Albumin and obesity- a systematic review Sumaia Radi¹, Abdulmalik Altaf ², Noura Eid³ ¹ Medical Technology Department, Faculty of Applied Medical Sciences/ KAU, SA ² Department of Surgery, Faculty of Medicine/ KAU, SA ³ Clinical Nutrition Department, Faculty of Applied Medical Sciences/ KAU, SA ABSTRACT Obesity is a chronic condition characterised by an accumulation of body fat. It is rapidly becoming an emerging disease in developed and developing countries due to the increasing westernisation of societies and change in the lifestyle. The aetiology of obesity is multifactorial, with a combination of genetic and environmental factors. There are three levels of obesity management: lifestyle modification (diet, physical activity and behaviour change), pharmacotherapy and bariatric surgery. Bariatric surgery is accepted nowadays as the most effective tool in the treatment and control of morbid obesity. Several studies have shownpre- and post-operative nutritional deficiency in obese patients. Additionally, Obesity is a chronic low grade inflammation state which lead to increase in C-Reactive Protein (CRP) and many nutrient deficiencies such as Serum albumin (SA). SA has been frequently used as an index of protein status and has been shown to correlate with risk for surgical complications and mortality.Little research has linked obesity and hypoalbuminaemia. In this review, we want to see whether there is a relation between morbidly obese patients, hypoalbuminaemia and CRP. Keywords: CRP, Hypoalbuminaemia, Inflammation, Obesity, Protein. 1. Introduction Obesity is a chronic condition characterised by an accumulation of body fat [1].
    [Show full text]